These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29702919)

  • 1. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.
    McEwan P; Ward T; Webster S; Yuan Y; Kalsekar A; Broglio K; Kamae I; Quintana M; Berry SM; Kobayashi M; Inoue S; Tang A; Kumada H
    Value Health Reg Issues; 2014 May; 3():136-145. PubMed ID: 29702919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.
    McEwan P; Ward T; Webster S; Yuan Y; Kalsekar A; Kamae I; Kobayashi M; Tang A; Kumada H
    Hepatol Res; 2016 Mar; 46(5):423-33. PubMed ID: 26440999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
    Lu Y; Jin X; Duan CA; Chang F
    PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
    Liu Y; Zhang H; Zhang L; Zou X; Ling L
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
    Ueno T; Osawa M; Imai Y; Ishikawa H; Garimella T
    J Clin Pharmacol; 2018 Nov; 58(11):1479-1488. PubMed ID: 30063245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
    Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
    Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
    Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
    Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis.
    Alavian SM; Rezaee-Zavareh MS
    Hepat Mon; 2016 Sep; 16(9):e41077. PubMed ID: 27826322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.
    Aygen B; Yıldız O; Akhan S; Çelen MK; Ural O; Koruk ST; Köse Ş; Korkmaz F; Kuruüzüm Z; Tuna N; Taheri S; Sayan M; Demir NA; Sümer Ş; Altınok ES
    Balkan Med J; 2015 Jul; 32(3):266-72. PubMed ID: 26185714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.
    Honda M; Sugawara Y; Watanabe T; Tateyama M; Tanaka M; Uchida K; Kawabata S; Yoshii D; Miura K; Isono K; Hayashida S; Ohya Y; Yamamoto H; Sasaki Y; Inomata Y
    Hepatol Res; 2017 Oct; 47(11):1147-1154. PubMed ID: 28002876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.